A study reported in MedPageToday finds:
“The addition of an anti-tumor necrosis factor (TNF) biologic agent early in the course of Crohn’s disease may improve the likelihood of clinical remission and possibly modify the course of the disease, researchers said.The combination of infliximab (Remicade) and azathioprine (Imuran) after failure of first-line therapy instead of holding it as the last option roughly doubled steroid-free remission and mucosal healing rates compared with azathioprine alone, William J. Sandborn, MD, of the Mayo Clinic in Rochester, Minn., and colleagues found.”
This is an interesting finding. I believe many GI’s still consider Remicade, Humira and other biologics as a last resort, and not being a medical professional, I’m not sure why. However, my personal experience with Remicade – very positive – makes me wonder if it shouldn’t be considered a first-line therapy in itself.